Is This Stock a Screaming Buy: Protalix BioTherapeutics, Inc. (:PLX)

Equity Research firms currently have a positive stance on shares of Protalix BioTherapeutics, Inc. (:PLX). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $2.15 on a short term basis.

At the time of writing, the stock was trading at $0.57. This represents a change from the opening price of -0.35%. In terms of performance, year to date, the stock is -45.59%. The monthly stock performance comes in at -9.02%. For the quarter, shares are performing at -14.10%. Weekly performance analysis shows the equity at -4.29%.

In taking a look at technical levels, shares are trading -7.19% away from the 50 day simple moving average and -25.57% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -54.56% away from it’s 52- week high and 3.27% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Protalix BioTherapeutics, Inc.’s RSI stands at 42.62. In looking at volatility levels, the shares saw weekly volatility of 4.18% and 4.64% over the past month.

Leave a Comment